A Study Evaluating the Onset-of-Action, Safety, and Efficacy of RDX227675 for the Treatment of Hyperkalemia
Status:
Terminated
Trial end date:
2017-05-01
Target enrollment:
Participant gender:
Summary
This phase 2, single-blind, placebo-controlled study will evaluate the onset-of-action,
safety, and efficacy of RDX227675 for the treatment of hyperkalemia. Subjects who qualify are
randomized into one of four treatment groups: Group 1 (Placebo qd), Group 2 (RDX227675 10 g
qd), Group 3 (RDX227675 20 g qd), Group 4 (RDX227675 30 g qd).